Exhibit 10.2

Task Order Number One
to Master Services Agreement Between
Corcept Therapeutics Inc. and Optime Care. Inc.

This Task Order Number One (the “Task Order”) is effective as of August 4, 2017
pursuant to, and as a part of, that certain Distribution Services Agreement (the
“Agreement”) effective August 4, 2017 between Corcept Therapeutics Inc.
(“Corcept”) and Optime Care, Inc. (“Optime”).

Product

For the purposes of this Task Order, “Product” means Korlym® and any other
medication sold by Corcept for the treatment of patients with hypcrcortisolism.

Territory

The United States of America

Optime Project Director

[****]

Corcept Representative

[****]

Optime Personnel

Optime will provide a team of skilled professionals sufficient to perform the
Services (the “Optime Team”), as set forth in Exhibit 1. Optime may [****],
provided it gives Corcept [****].

SOPs and Financial Controls

The SOPs and Financial Controls Optime will implement in connection with the
Services are listed in Exhibit 2. Optime may [****], provided it [****]. Optime
shall provide Corcept with full documentation for all SOPs and Financial
Controls applicable to the Services.

Services Performed and Key Performance Metrics

Pharmacy and related patient and physician support and financial reporting
services (the “Services”).

Corcept and Optime understand and agree that the effectiveness of the Services
can be measured by reference to the key performance metrics set forth in Exhibit
3 to this Task Order (the “KPMs”). Optime will use [****] to meet or exceed the
KPMs. Corcept will provide Optime with such data as Optime reasonably requires
to gauge its performance with respect to the KPMs and make improvements where
appropriate. Corcept may [****], provided it [****].

 

1

[****] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended. Confidential treatment has been requested with respect to the omitted
portions.

--------------------------------------------------------------------------------

 

Project Schedule and Termination Date

Start Date: On or about August 7. 2017.

Termination Date: Five years, unless terminated earlier as set forth in the
Agreement.

Services Fees

Unless the Parties agree otherwise, Corcept shall pay Optime Fees as set forth
in Exhibit 4 to this Task Order and pursuant to the terms in the Agreement.

Product Complaint Contact

Optime:Corcept Team Pharmacist (attn. [****]) [****]

Corcept:Director, Quality Assurance (attn. [****]); [****]

Adverse Event Contact

Optime:Corcept Team Pharmacist (attn. [****]) [****]

Corcept: Ashfteld Pharmacovigilance
[****]

 

 

In Witness Whereof, the Parties have caused this Task Order to be executed by
their duly authorized representatives. The Parties acknowledge that the date of
signature may not be the effective date of this Task Order.

 

Concept Therapeutics Inc.

Optime Care, Inc.

By:

 

By:

 

Print Name:

 

Print Name:

 

Title:

 

Title:

 

Date:

 

Date:

 

 

 

 

2

 

[****] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended. Confidential treatment has been requested with respect to the omitted
portions.

--------------------------------------------------------------------------------

 

Exhibit 1
Optime Team

Optime will dedicate a team whose sole responsibilities will be performing the
Services set forth in the Agreement and Task Order One. The team will consist of
personnel filling the following roles:

One Team Vice President. The Team Vice President will manage the day-to-day
operations of the team and be responsible for all activities related to the
Services. [****] will fill this role.

[****] Care Coordinators. Care Coordinators will be the primary points of
contact for patients and prescribing physicians, with responsibilities including
patient welcoming, all reimbursement activities, and coordination of medication
delivery. The Care Coordinator team will consist of [****].

One Team Pharmacist. The Team Pharmacist will fulfill all pharmacy duties
related to the Services, including, but not limited to, patient counseling,
adverse event reporting, product distribution and clinical education. [****]
will be the Team Pharmacist.

As provided in Section 6 of the Agreement and in Task Order One, [****]. The
parties agree to amend and restate this Exhibit 1 promptly if there is a change
to the Optime Team.

 

 

3

[****] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended. Confidential treatment has been requested with respect to the omitted
portions.

 

--------------------------------------------------------------------------------

 

Exhibit 2
Financial Controls

 

[*****]

1

[*****] = Five pages of confidential information, marked by brackets, have been
omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Confidential treatment has been requested with respect to the omitted portions.

--------------------------------------------------------------------------------

 

Exhibit 2
Standing Operating Procedures

 

[*****]

2

[*****] = Four pages of confidential information, marked by brackets, have been
omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Confidential treatment has been requested with respect to the omitted portions.

--------------------------------------------------------------------------------

 

Exhibit 3
Key Performance Metrics

[****]

 

[****] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended. Confidential treatment has been requested with respect to the omitted
portions.

--------------------------------------------------------------------------------

 

Exhibit 4
Service Fees

[****]

 

[****] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended. Confidential treatment has been requested with respect to the omitted
portions.